Background The rapidly expanding clinical adaptation of prostate-specific membrane
antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has …

In the past decade, a growing body of literature has reported promising results for prostate-
specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate …

Purpose Since the clinical introduction of 68 Ga-PSMA-11 PET/CT, this imaging method has
rapidly spread and is now regarded as a significant step forward in the diagnosis of …

As medical imaging has grown progressively more complicated and subspecialized in
recent decades, several standardized reporting systems have been proposed for a variety of …

Background Prostate-specific membrane antigen (PSMA) is the up-and-coming target for
molecular imaging of prostate cancer. Despite its name, non-prostate-related PSMA …

Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool
for managing patients with recurrent prostate cancer, and one of the most frequently …

The continuing adoption of prostate specific membrane antigen (PSMA)-targeted PET for
prostate cancer molecular imaging requires imagers and clinicians alike to be aware of the …

Purpose We studied the usefulness of 68 Ga-prostate-specific membrane antigen (PSMA)
PET/CT for detecting relapse in a prospective series of patients with biochemical recurrence …

Metastatic renal cell carcinoma (mRCC) is a disease that portends poor prognosis despite
an increasing number of novel systemic treatment options including new targeted therapies …

Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer epithelium,
making it a promising target for molecular imaging and therapy. Recently, several studies …